Edwards Lifesciences Co. (NYSE:EW) Stock Position Lifted by Cetera Advisors LLC

Cetera Advisors LLC lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,526 shares of the medical research company’s stock after purchasing an additional 156 shares during the quarter. Cetera Advisors LLC’s holdings in Edwards Lifesciences were worth $1,465,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Advisors Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% in the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after buying an additional 117 shares during the period. Apollon Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 1.0% in the first quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after buying an additional 119 shares during the period. Geller Advisors LLC boosted its holdings in Edwards Lifesciences by 6.5% during the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock worth $231,000 after purchasing an additional 120 shares during the last quarter. Private Trust Co. NA boosted its holdings in Edwards Lifesciences by 1.1% during the second quarter. Private Trust Co. NA now owns 11,410 shares of the medical research company’s stock worth $1,076,000 after purchasing an additional 125 shares during the last quarter. Finally, Bangor Savings Bank boosted its holdings in Edwards Lifesciences by 18.3% during the second quarter. Bangor Savings Bank now owns 839 shares of the medical research company’s stock worth $79,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 79.25% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of Edwards Lifesciences from $83.00 to $68.00 and set a “neutral” rating for the company in a report on Thursday, October 26th. TheStreet cut shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th. Citigroup reduced their target price on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Jefferies Financial Group increased their target price on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the stock a “buy” rating in a report on Tuesday, July 25th. Finally, Leerink Partnrs reaffirmed a “market perform” rating on shares of Edwards Lifesciences in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $84.29.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $77.79, for a total value of $564,366.45. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,497,301.92. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $77.79, for a total value of $564,366.45. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,497,301.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $75.86, for a total transaction of $2,226,491.00. Following the completion of the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $340,307.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,795 shares of company stock worth $12,724,914. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.4 %

Shares of Edwards Lifesciences stock opened at $67.19 on Tuesday. The firm’s 50-day moving average price is $68.93 and its two-hundred day moving average price is $79.38. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $94.87. The company has a quick ratio of 2.45, a current ratio of 3.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $40.75 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 3.74 and a beta of 1.02.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.59. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.48 billion. During the same period last year, the company posted $0.61 EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.